BR112015027607A8 - métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. - Google Patents
métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.Info
- Publication number
- BR112015027607A8 BR112015027607A8 BR112015027607A BR112015027607A BR112015027607A8 BR 112015027607 A8 BR112015027607 A8 BR 112015027607A8 BR 112015027607 A BR112015027607 A BR 112015027607A BR 112015027607 A BR112015027607 A BR 112015027607A BR 112015027607 A8 BR112015027607 A8 BR 112015027607A8
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- methods
- fgfr1
- patients
- carcinoid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 208000002458 carcinoid tumor Diseases 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 101100227089 Danio rerio fgfr1a gene Proteins 0.000 abstract 7
- 230000004927 fusion Effects 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 3
- 101150019331 FGF2 gene Proteins 0.000 abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 2
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 abstract 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 2
- 230000004544 DNA amplification Effects 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 101150016624 fgfr1 gene Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015027607A2 BR112015027607A2 (pt) | 2017-12-05 |
| BR112015027607A8 true BR112015027607A8 (pt) | 2018-01-23 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027607A BR112015027607A8 (pt) | 2013-05-01 | 2014-04-30 | métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (https=) |
| EP (1) | EP2991669A2 (https=) |
| JP (1) | JP2016526016A (https=) |
| KR (1) | KR20160003141A (https=) |
| CN (1) | CN105188732A (https=) |
| AU (1) | AU2014259956A1 (https=) |
| BR (1) | BR112015027607A8 (https=) |
| CA (1) | CA2908391A1 (https=) |
| HK (1) | HK1213817A1 (https=) |
| MX (1) | MX2015015115A (https=) |
| RU (1) | RU2015150233A (https=) |
| SG (1) | SG11201508878WA (https=) |
| WO (1) | WO2014179448A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP2015505818A (ja) | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2626679C (en) * | 2005-11-04 | 2011-08-16 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP5945277B2 (ja) * | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ１細胞外ドメイン併用療法 |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| JP2015505818A (ja) * | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
-
2014
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201508878WA (en) | 2015-11-27 |
| WO2014179448A3 (en) | 2014-12-24 |
| KR20160003141A (ko) | 2016-01-08 |
| AU2014259956A1 (en) | 2015-11-12 |
| WO2014179448A2 (en) | 2014-11-06 |
| US20160067307A1 (en) | 2016-03-10 |
| RU2015150233A (ru) | 2017-06-02 |
| EP2991669A2 (en) | 2016-03-09 |
| JP2016526016A (ja) | 2016-09-01 |
| US20180280470A1 (en) | 2018-10-04 |
| BR112015027607A2 (pt) | 2017-12-05 |
| CN105188732A (zh) | 2015-12-23 |
| CA2908391A1 (en) | 2014-11-06 |
| HK1213817A1 (zh) | 2016-07-15 |
| MX2015015115A (es) | 2016-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027607A8 (pt) | métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. | |
| MX2024000614A (es) | Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer. | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| BR112015009752A2 (pt) | conjugados de anticorpo/fármaco e métodos de uso | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| HK1201462A1 (en) | Methods of treating cancer | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| HK1253507A1 (zh) | 抗 ror1 抗体 | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
| MX373231B (es) | Agente anticancerigeno. | |
| MX392408B (es) | Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina). | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
| PH12015501709A1 (en) | Administration of an-activin-a compound to a subject | |
| MX381399B (es) | Formulaciones de coenzima q10 y métodos de uso. | |
| BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |